Madar Ahmed A, Knutsen Kirsten V, Stene Lars C, Brekke Mette, Lagerløv Per, Meyer Haakon E, Macdonald Helen M
Department of Community Medicine, Institute of Health and Society, University of Oslo, Norway.
Department of General Practice, Institute of Health and Society, University of Oslo, Norway.
Bone Rep. 2015 May 21;2:82-88. doi: 10.1016/j.bonr.2015.05.004. eCollection 2015 Jun.
Vitamin D is essential for the maintenance of calcium homeostasis and bone mineralization; and low serum 25-hydroxyvitamin D (s-25-(OH)D) concentrations are associated with increased bone turnover. However, there is a lack of randomized controlled trials that have investigated the effect of vitamin D treatment on bone turnover in immigrant populations. We aimed to investigate the effect of 16-week daily vitamin D supplementation on bone formation marker serum procollagen type 1 amino-terminal propeptide (P1NP) and bone resorption marker C-terminal crosslinked telopeptide of type I collagen (CTX).
Double-blind, randomized, placebo-controlled trial.
Immigrant community centers in Oslo, Norway.
251 healthy adults aged 18-50 years with a non-Western immigrant background were recruited.
16 weeks of daily oral supplementation with either 10 μg vitamin D, 25 μg vitamin D, or placebo.
Difference in change during the 16-week intervention between the intervention groups combined (10 or 25 μg of vitamin D/day) and placebo, in serum P1NP and serum CTX.
A total of 214 (85%) participants completed the study. S-25-(OH)D increased from 29 nmol/L at baseline to 49 nmol/L in the intervention group with no significant change in the placebo group. However, there was no difference in change of serum P1NP (mean difference: - 1.2 μg/L (95% CI: - 5.4, 2.9, P = 0.6)) and serum CTX (mean difference: - 0.005 μg/L (95% CI: - 0.03, 0.02, P = 0.7)) between those receiving vitamin D supplementation compared with placebo. The plasma PTH had decreased by a mean of - 1.97 pmol/L (95% CI: - 2.7, - 1.3, P < 0.0001) in the vitamin D group compared to placebo.
Supplementation with 10 or 25 μg oral vitamin D during winter and spring for 16 weeks did not significantly affect serum P1NP and serum CTX, despite increasing s-25(OH)D and decreasing PTH in a healthy immigrant population with low baseline vitamin D status. Trial registration number: NCT01263288.
维生素D对于维持钙稳态和骨矿化至关重要；血清25-羟基维生素D（s-25-(OH)D）浓度低与骨转换增加有关。然而，缺乏针对移民人群中维生素D治疗对骨转换影响的随机对照试验。我们旨在研究每日补充维生素D 16周对骨形成标志物血清1型前胶原氨基端前肽（P1NP）和骨吸收标志物1型胶原C端交联端肽（CTX）的影响。
双盲、随机、安慰剂对照试验。
挪威奥斯陆的移民社区中心。
招募了251名年龄在18至50岁之间、具有非西方移民背景的健康成年人。
每日口服补充10μg维生素D、25μg维生素D或安慰剂，为期16周。
联合干预组（每日10或25μg维生素D）与安慰剂组在16周干预期间血清P1NP和血清CTX变化的差异。
共有214名（85%）参与者完成了研究。干预组的s-25-(OH)D从基线时的29nmol/L升至49nmol/L，而安慰剂组无显著变化。然而，与安慰剂组相比，接受维生素D补充的人群血清P1NP（平均差异：-1.2μg/L（95%CI：-5.4，2.9，P = 0.6））和血清CTX（平均差异：-0.005μg/L（95%CI：-0.03，0.02，P = 0.7））的变化无差异。与安慰剂组相比，维生素D组的血浆甲状旁腺激素平均下降了-1.97pmol/L（95%CI：-2.7，-1.3，P < 0.0001）。
在冬季和春季，对基线维生素D水平较低的健康移民人群口服补充10或25μg维生素D 16周，尽管s-25(OH)D升高且甲状旁腺激素降低，但对血清P1NP和血清CTX无显著影响。试验注册号：NCT01263288。
